Capricor Therapeutics, Inc. (CAPR)
9.91
+0.32
(+3.34%)
USD |
NASDAQ |
Aug 31, 16:00
10.37
+0.46
(+4.64%)
After-Hours: 04:52
Capricor Therapeutics Total Long Term Debt (Quarterly) : 89.56M for June 30, 2026
Total Long Term Debt (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Long Term Debt (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 89.56M |
| March 31, 2026 | 20.28M |
| December 31, 2025 | 17.74M |
| September 30, 2025 | 17.80M |
| June 30, 2025 | 3.571M |
| March 31, 2025 | 3.784M |
| December 31, 2024 | 3.993M |
| September 30, 2024 | 4.211M |
| June 30, 2024 | 4.420M |
| March 31, 2024 | 4.626M |
| December 31, 2023 | 4.863M |
| September 30, 2023 | 5.060M |
| June 30, 2023 | 4.894M |
| March 31, 2023 | 5.076M |
| December 31, 2022 | 5.254M |
| September 30, 2022 | 5.459M |
| June 30, 2022 | 5.535M |
| March 31, 2022 | 5.682M |
| December 31, 2021 | 5.829M |
| September 30, 2021 | 3.376M |
| June 30, 2021 | 3.376M |
| March 31, 2021 | 3.694M |
| December 31, 2020 | 3.694M |
| September 30, 2020 | 3.694M |
| June 30, 2020 | 3.694M |
| Date | Value |
|---|---|
| March 31, 2020 | 3.376M |
| December 31, 2019 | 3.376M |
| September 30, 2019 | 3.376M |
| June 30, 2019 | 3.376M |
| March 31, 2019 | 3.376M |
| December 31, 2018 | 3.376M |
| September 30, 2018 | 3.376M |
| June 30, 2018 | 3.376M |
| March 31, 2018 | 3.376M |
| December 31, 2017 | 3.376M |
| September 30, 2017 | 17.53M |
| June 30, 2017 | 17.26M |
| March 31, 2017 | 17.01M |
| December 31, 2016 | 17.01M |
| September 30, 2016 | 17.01M |
| June 30, 2016 | 12.16M |
| March 31, 2016 | 10.16M |
| December 31, 2015 | 9.156M |
| September 30, 2015 | 9.156M |
| June 30, 2015 | 9.156M |
| March 31, 2015 | 9.156M |
| December 31, 2014 | 9.156M |
| September 30, 2014 | 9.156M |
| June 30, 2014 | 8.642M |
| March 31, 2014 | 3.962M |
Total Long Term Debt Definition
Represents a company's total debt maturing for more than 12 months of the reporting period.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Long Term Debt (Quarterly) Benchmarks
| REGENXBIO, Inc. | 243.11M |
| Cytokinetics, Inc. | 1.250B |
| Emergent BioSolutions, Inc. | 586.70M |
| Rigel Pharmaceuticals, Inc. | 39.29M |
| United Therapeutics Corp. | 0.00 |